To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Radient Signs Full Service Distribution Agreement with Naroo in Korea
Read time: Less than a minute
Through its subsidiary AMDL Diagnostics Inc., Radient Pharmaceuticals Corporation has announced that it has entered into a five-year full-service distribution agreement with Naroo Ditech Inc. to expand the Company's Onko-Sure® IVD cancer test throughout the Korean healthcare market.
Under the terms of the agreement, Naroo Ditech has committed to purchase a minimum of 3,352 Onko-Sure® test kits over the duration of the partnership. Naroo Ditech will represent RPC while obtaining regulatory clearances and providing marketing, sales, and distribution services for Onko-Sure® in diagnostic centers and clinical labs throughout the Korean market.
Marketing, sales and distribution services include developing product localization strategies; representing Radient Pharmaceuticals and its Onko-Sure® IVD cancer test at relevant healthcare conferences and events; incorporating relevant product information on the Naroo corporate website. Additionally, Naroo Ditech will provide a dedicated customer service team to respond to customer inquiries and technical questions.
Onko-Sure® is a simple, noninvasive, patent-pending and regulatory-approved in vitro diagnostic test that enables physicians and their patients to monitor and/or detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). FDP levels rise with the progression of cancer. Onko-Sure® is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada for lung cancer detection and treatment monitoring.
Under the terms of the agreement, Naroo Ditech has committed to purchase a minimum of 3,352 Onko-Sure® test kits over the duration of the partnership. Naroo Ditech will represent RPC while obtaining regulatory clearances and providing marketing, sales, and distribution services for Onko-Sure® in diagnostic centers and clinical labs throughout the Korean market.
Marketing, sales and distribution services include developing product localization strategies; representing Radient Pharmaceuticals and its Onko-Sure® IVD cancer test at relevant healthcare conferences and events; incorporating relevant product information on the Naroo corporate website. Additionally, Naroo Ditech will provide a dedicated customer service team to respond to customer inquiries and technical questions.
Onko-Sure® is a simple, noninvasive, patent-pending and regulatory-approved in vitro diagnostic test that enables physicians and their patients to monitor and/or detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). FDP levels rise with the progression of cancer. Onko-Sure® is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada for lung cancer detection and treatment monitoring.
